Pegylated Interferon Lambda for Treatment of COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A randomized, open-label, 2 arm, pilot trial of Lambda 180 mcg administered subcutaneously
once weekly, for up to two weeks (2 injections at most), in addition to standard supportive
care, compared to standard supportive care alone, in a population of COVID-19 infected
patients.
patients will be randomized according to 1:1 ratio to one of the 2 trial arms: Lambda 180 mcg
S.C + standard care (intervention arm) or standard care only (control arm).